Regado Biosciences Inc  

(Public, NASDAQ:RGDO)   Watch this stock  
Find more results for Carol J. Cooper�
1.22
-0.07 (-5.43%)
Apr 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.21 - 1.31
52 week 0.80 - 7.36
Open 1.31
Vol / Avg. 147,248.00/391,914.00
Mkt cap 41.00M
P/E     -
Div/yield     -
EPS -2.41
Shares 33.61M
Beta     -
Inst. own 52%
Jan 20, 2015
Regado Biosciences and Tobira Therapeutics Merger Agreement Call
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -56.49% -134.02%
Return on average equity -132.15% -285.40%
Employees 4 -
CDP Score - -

Address

120 Mountainview Blvd
BASKING RIDGE, NJ 07920-3454
United States - Map
+1-908-5802111 (Phone)
+1-908-3250406 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Regado Biosciences, Inc. is a biopharmaceutical company focused on the discovery and development of actively controllable antithrombotic drug systems for acute and sub-acute cardiovascular indications. The Company is pioneering the discovery and development of two-component drug systems consisting of a therapeutic aptamer and its specific active control agent. REG1 is an actively controllable anticoagulant targeting coagulation Factor IXa for use in patients with a range of acute coronary syndromes (ACS), undergoing a percutaneous coronary intervention (PCI), a hospital-based procedure used to mechanically open or widen obstructed coronary arteries. REG1 consists of pegnivacogin, an anticoagulant aptamer, and its specific active control agent, anivamersen. Pegnivacogin achieves its maximal anticoagulant effect within five minutes of injection.

Officers and directors

Dennis G. Podlesak MBA Chairman of the Board
Age: 57
Bio & Compensation  - Reuters
Christopher P. Rusconi Ph.D. Senior Vice President - Discovery/Preclinical Development , Chief Scientific Officer
Age: 46
Bio & Compensation  - Reuters
Nicholas J. Pelliccione Ph.D. Senior Vice President - Regulatory Affairs and Quality Assurance
Bio & Compensation  - Reuters
Christopher E. Courts CPA Vice President - Finance
Age: 44
Bio & Compensation  - Reuters
Carol L. Brosgart M.D. Director
Age: 63
Bio & Compensation  - Reuters
Jeffrey H. Cooper CPA Director
Age: 59
Bio & Compensation  - Reuters
Laurent Fischer M.D. Director
Age: 51
Bio & Compensation  - Reuters
Andrew J. Fromkin Director
Age: 47
Bio & Compensation  - Reuters
Patrick J. Heron Director
Age: 44
Bio & Compensation  - Reuters